Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  Cyclacel Pharmaceuticals Inc    

 SummaryChartsNewsCalendarCompanyFinancialsConsensusRevisions 
Financials ($)
Sales 2016 1,21 M
EBIT 2016 -15,0 M
Net income 2016 -11,9 M
Debt 2016 -
Yield 2016 -
Sales 2017 1,63 M
EBIT 2017 -26,0 M
Net income 2017 -22,7 M
Debt 2017 -
Yield 2017 -
P/E ratio 2016 -
P/E ratio 2017
Capi. / Sales2016 18,7x
Capi. / Sales2017 13,9x
Capitalization 22,6 M
More Financials
Company
Cyclacel Pharmaceuticals, Inc. is a diversified biopharmaceutical business focused in hematology and oncology based on a development pipeline of novel drug candidates.It is engaged in discovery, development and commercialization of novel, mechanism-targeted drugs to treat cancer and other serious... 
More about the company
Latest news on CYCLACEL PHARMACEUTICALS I
09/21 STOCKS IN ACTION : Pfizer, Inc. Cyclacel Pharmaceuticals, Inc.
09/12 CYCLACEL PHARMACEUTICALS, INC. : Other Events (form 8-K)
09/07 CYCLACEL PHARMACEUTICALS : Cyclacels CYC065 Demonstrates Promising Activity in M..
09/06 Cyclacel’s CYC065 Demonstrates Promising Activity in MYCN-Addicted Neur..
08/30 CYCLACEL PHARMACEUTICALS, INC. : Other Events, Financial Statements and Exhibits..
08/11 CYCLACEL PHARMACEUTICALS : Management's Discussion and Analysis of Financial Con..
08/10 CYCLACEL PHARMACEUTICALS, INC. : Results of Operations and Financial Condition, ..
08/10 Cyclacel Pharmaceuticals Reports 2nd Quarter 2016 Financial Results
08/03 CYCLACEL PHARMACEUTICALS : Cyclacels CYC065 Demonstrates Promising Activity in U..
08/03 Cyclacel Pharmaceuticals to Release Second Quarter 2016 Financial Results
More news
Sector news : Bio Therapeutic Drugs
09/29DJARROWHEAD PHARMACEUTICALS : Amgen, Arrowhead Pharma Agree to Cardiovascular Coll..
09/27DJAMGEN : Myeloma Treatment Study Fails to Meet Primary Endpoint
09/26DJSANOFI : FDA Accepts Sanofi's, Regeneron's Dermatitis Treatment for Priority Rev..
09/23DJAMGEN : FDA Approves Amgen's Biosimilar Version of Humira -- 2nd Update
09/23DJAMGEN : FDA Approves Amgen's Biosimilar Version of Humira -- Update
More sector news : Bio Therapeutic Drugs
News from SeekingAlpha
06/07 Midday Gainers / Losers
06/06 Midday Gainers / Losers
06/06 Cyclacel's lead product candidates show encouraging results in early-stage st..
06/06 HEALTHCARE - TOP 5 GAINERS / LOSERS : 00 am
06/02 Some Ideas For The Next Celator
Advertisement
Chart CYCLACEL PHARMACEUTICALS I
Duration : Period :
Cyclacel Pharmaceuticals I Technical Analysis Chart | US23254L3069 | 4-Traders
Full-screen chart
Income Statement Evolution
More Financials
Consensus 
Mean consensus OUTPERFORM
Number of Analysts 1
Average target price 60,0 $
Spread / Average Target 900%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Spiro Rombotis President, Chief Executive Officer & Director
David C. U'Prichard Chairman
Paul McBarron COO, CFO, Secretary, Director & Executive VP
David Glover Chief Scientist
John Michael Middlecott Banham Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
CYCLACEL PHARMACEUTICA..7.17%23
AMGEN, INC.4.55%127 004
GILEAD SCIENCES, INC.-21.96%104 213
CELGENE CORPORATION-11.63%82 030
REGENERON PHARMACEUTIC..-22.80%44 129
VERTEX PHARMACEUTICALS..-29.40%22 013
More Results